Compare SHASUN PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA AUROBINDO PHARMA SHASUN PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 123.9 10.2 1,209.6% View Chart
P/BV x 8.5 1.9 451.0% View Chart
Dividend Yield % 0.2 0.6 41.9%  

Financials

 SHASUN PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
AUROBINDO PHARMA
Mar-19
SHASUN PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs94830 11.3%   
Low Rs46527 8.7%   
Sales per share (Unadj.) Rs214.2333.9 64.1%  
Earnings per share (Unadj.) Rs5.340.4 13.2%  
Cash flow per share (Unadj.) Rs15.851.8 30.6%  
Dividends per share (Unadj.) Rs1.002.50 40.0%  
Dividend yield (eoy) %1.40.4 388.3%  
Book value per share (Unadj.) Rs53.3237.1 22.5%  
Shares outstanding (eoy) m56.62585.91 9.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.0 16.1%   
Avg P/E ratio x13.116.8 77.9%  
P/CF ratio (eoy) x4.413.1 33.7%  
Price / Book Value ratio x1.32.9 45.8%  
Dividend payout %18.76.2 302.5%   
Avg Mkt Cap Rs m3,958397,569 1.0%   
No. of employees `000NA17.9 0.0%   
Total wages/salary Rs m2,16425,849 8.4%   
Avg. sales/employee Rs ThNM10,956.9-  
Avg. wages/employee Rs ThNM1,447.7-  
Avg. net profit/employee Rs ThNM1,324.3-  
INCOME DATA
Net Sales Rs m12,127195,636 6.2%  
Other income Rs m2291,553 14.8%   
Total revenues Rs m12,356197,189 6.3%   
Gross profit Rs m1,00939,519 2.6%  
Depreciation Rs m5946,680 8.9%   
Interest Rs m4152,626 15.8%   
Profit before tax Rs m23031,767 0.7%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m-737,269 -1.0%   
Profit after tax Rs m30223,645 1.3%  
Gross profit margin %8.320.2 41.2%  
Effective tax rate %-31.722.9 -138.4%   
Net profit margin %2.512.1 20.6%  
BALANCE SHEET DATA
Current assets Rs m6,884153,645 4.5%   
Current liabilities Rs m8,456120,429 7.0%   
Net working cap to sales %-13.017.0 -76.3%  
Current ratio x0.81.3 63.8%  
Inventory Days Days62135 45.6%  
Debtors Days Days10864 168.9%  
Net fixed assets Rs m4,970103,909 4.8%   
Share capital Rs m113586 19.3%   
"Free" reserves Rs m2,875138,322 2.1%   
Net worth Rs m3,020138,908 2.2%   
Long term debt Rs m1,8171,800 101.0%   
Total assets Rs m13,347264,544 5.0%  
Interest coverage x1.613.1 11.9%   
Debt to equity ratio x0.60 4,645.0%  
Sales to assets ratio x0.90.7 122.9%   
Return on assets %5.49.9 54.1%  
Return on equity %10.017.0 58.8%  
Return on capital %13.323.8 55.9%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84397,316 6.0%   
Fx outflow Rs m2,17340,589 5.4%   
Net fx Rs m3,66956,727 6.5%   
CASH FLOW
From Operations Rs m39816,220 2.5%  
From Investments Rs m-1,635-28,768 5.7%  
From Financial Activity Rs m1,30919,191 6.8%  
Net Cashflow Rs m716,656 1.1%  

Share Holding

Indian Promoters % 39.2 54.1 72.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 8.0 45.3%  
FIIs % 17.6 27.7 63.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 10.2 388.2%  
Shareholders   20,750 69,601 29.8%  
Pledged promoter(s) holding % 12.3 8.6 143.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   VENUS REMEDIES  DR. REDDYS LAB  GSK PHARMA  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Inflation and Onion Effect: Your Inside Scoop on the Markets(Podcast)

Stock markets remained rangebound this week too. Macroeconomic news globally and domestically remained the focus of the week.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

Make the Most of the Smallcap Rebound with These Stocks(Profit Hunter)

Dec 3, 2019

Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.

What Is the IPO Euphoria Signaling Us About the Markets?(The 5 Minute Wrapup)

Dec 2, 2019

2019 will be remembered as the year of great money-making IPOs...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - ABBOTT INDIA COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS